Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer

There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Sohei, Hiwasa, Takaki, Ishige, Takayuki, Kano, Masayuki, Hoshino, Tyuji, Rahmutulla, Bahityar, Seimiya, Masanori, Shimada, Hideaki, Nomura, Fumio, Matsubara, Hisahiro, Matsushita, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894018/
https://www.ncbi.nlm.nih.gov/pubmed/33306856
http://dx.doi.org/10.1111/cas.14767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894018/
https://www.ncbi.nlm.nih.gov/pubmed/33306856
http://dx.doi.org/10.1111/cas.14767

Ejemplares similares